Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Guidance
Summary
Jazz Pharmaceuticals plc announced its financial results for the first quarter of 2024, showing a 1% increase in total revenues to $901.98 million. The company reported a GAAP net loss of $14.6 million or $0.23 per diluted share, compared to a net income of $69.4 million or $1.04 per diluted share in the same period of 2023. Non-GAAP adjusted net income was $182.2 million or $2.68 per diluted share. The company affirmed its 2024 financial guidance with total revenues expected between $4.0 and $4.2 billion. Key growth drivers included Xywav, Epidiolex, and Rylaze, with oncology revenues growing by 13%. The company also advanced its pipeline with key catalysts expected in the near term.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement